Clinical Scorecard: Comparative Analysis of Circular and Linear mRNA Vectors: Expression Efficacy and Immunization Strategies
At a Glance
Category
Detail
Condition
mRNA vector technology for vaccine and therapeutic protein expression
Key Mechanisms
Linear mRNA vectors are cap-dependent and rely on 5' cap structures and UTRs for expression; circular mRNA vectors are cap-independent and utilize Internal Ribosome Entry Sites (IRES) for translation initiation
Target Population
Individuals receiving mRNA-based vaccines or therapies, including SARS-CoV-2 immunization and passive immunization models
Care Setting
Vaccine development and therapeutic protein production in research and clinical settings
Key Highlights
Modified linear mRNA vectors with advanced capping (CleanCap AG) show significantly higher expression levels in vitro and in vivo compared to circular vectors.
Active immunization with circular mRNA vectors yields immunogenicity and protective activity comparable to linear vectors despite lower expression levels.
Passive immunization requiring high protein expression favors linear mRNA vectors due to their superior protein production.
Guideline-Based Recommendations
Diagnosis
Evaluate mRNA vector type based on intended immunization strategy (active vs passive) and required protein expression levels.
Management
Use linear mRNA vectors with N1-methylpseudouridine modification and CleanCap AG capping for enhanced protein expression.
Consider circular mRNA vectors with optimized IRES elements (e.g., CVB3 or HRV B6) for active immunization applications.
Monitoring & Follow-up
Monitor protein expression levels and immunogenicity outcomes to assess vector performance in vivo.
Risks
No specific risks detailed; however, vector choice impacts expression efficiency and immunization efficacy.
Patient & Prescribing Data
Recipients of mRNA vaccines or passive immunization therapies targeting viral pathogens such as SARS-CoV-2
Linear mRNA vectors provide higher protein expression beneficial for passive immunization, while circular vectors achieve comparable immunogenicity in active immunization despite lower expression.
Clinical Best Practices
Select linear mRNA vectors with N1-methylpseudouridine and CleanCap AG capping for applications requiring high protein yield.
Employ circular mRNA vectors with effective IRES sequences for active immunization where moderate expression suffices.
Utilize alfa-globin UTRs in linear mRNA constructs to enhance stability and translation efficiency.
Consider the immunization context (active vs passive) when choosing between linear and circular mRNA platforms.
by Vladimir M. Vakhtinskii, Irina L. Tutykhina, Alina S. Dzharullaeva, Daria M. Grousova, Ilya D. Zorkov, Anna A. Ilyukhina, Dmitrii A. Reshetnikov, Valentin V. Azizyan, Artem A. Derkaev, Evgeniia N. Bykonia, Evgeny V. Usachev, Denis A. Kleymenov, Vladimir A. Gushchin, Inna V. Shuliakova, Dmitry V. Shcheblyakov, Maxim M. Shmarov, Denis Yu. Logunov, Alexander L. Gintsburg
